X0609 4 2026-06-04 0 0002022416 Silexion Therapeutics Corp SLXN 0001727789 Shirvan Mitchell true C/O SILEXION THERAPEUTICS CORP 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606 ISRAEL 0 1 0 0 CSO and CDO 0 Ordinary Shares 2026-06-04 4 A 0 6000 0 A 8789 D Stock Option (right to buy Ordinary Shares) 9077.10 2024-08-15 2032-06-07 Ordinary Shares 48 48 D The number of ordinary shares, par value $0.135 per share ("ordinary shares"), reported in this Form 4 reflects an adjustment relative to the last Form 4 filed by the Reporting Person on March 30, 2026 due to the 1-for-10 reverse share split effected by the Issuer on May 28, 2026 (which caused the 27,889 ordinary shares, par value $0.0135, beneficially owned by the Reporting Person as reported in that Form 4 to become 2,789 ordinary shares, par value $0.135, prior to the grant reported in this Form 4). The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, in respect of the Reporting Person's services as an officer of the Issuer. The grant was approved by the Issuer's board of directors. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. The number of options to purchase ordinary shares, underlying ordinary shares, and the exercise price of those options reported in this row have been adjusted to reflect the 1-for-10 reverse share split effected by the Issuer on May 28, 2026 (which caused the 478 options to purchase 478 ordinary shares, par value $0.0135, at an exercise price of $907.71 per share, beneficially owned by the Reporting Person, as reported in that Form 4, to become 48 options to purchase 48 ordinary shares, par value $0.135, at an exercise price of $9,077.10 per share). /s/ Mirit Horenshtein Hadar, Attorney-in-fact 2026-06-08